Unproven stem cell-based interventions & harm to existing & future patients

Cell & Gene Therapy Insights 2022; 8(3), 397–401

DOI: 10.18609/cgti.2022.057

Published: 27 March 2022
Flora Naylor, Kirstin RW Matthews

“To address these risks to current and future patients, companies developing SCBIs should work with policymakers and patient advocates to protect clinical research and the reputation of the field.”